Translate
Immunitybio, Inc.
About
7.22USD-0.52 -6.72%
Closed • Updated at 13:10 GMT+00:00Market Cap$7.56B
Volume17.94M
Beta1.80
RSI42.79
Gross Margin87.93%
Immunitybio, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 22 2026
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
May 22 2026
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
May 21 2026
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
May 18 2026
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
May 16 2026
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Recent Videos
Dr. Patrick Soon-Shiong, physician and founder of ImmunityBio, is one of the most credentialed.
May 22, 2026
ImmunityBio: ANKTIVA Did This With US Sales Alone (Europe Could Be Next!)
May 20, 2026
ImmunityBio's 668% Revenue Explosion Makes IBRX a Must-Own Now! | IBRX Stock Analysis
May 20, 2026
IBRX Stock (ImmunityBio stock analysis) IBRX STOCK PREDICTION & analysis & news today
May 20, 2026
Community Chat
Ask AI
Try asking